Chemotherapy, anti-HER-2 therapy (transtuzumab), tyrosine kinase receptor inhibitors (TKIs) (lapatinib), and endocrine therapy have achieved treatment effects in HER2-positive breast cancer (7–9). Here, ERBB2 is linked to breast carcinoma.